Newsfile·2025-11-24 21:55Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 15, 2025, and can do so by contacting Rosen Law Firm [4][7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [5]. Group 3: Case Allegations - The lawsuit alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, which led to investor losses when the truth was revealed [6].